Achilles Therapeutics sold its cancer immunotherapy tech to AstraZeneca for $12 million.
Achilles Therapeutics has sold its technology assets to AstraZeneca for $12 million. This deal involves the transfer of Achilles' proprietary technologies, which are designed to identify and develop personalized cancer immunotherapies. The sale marks a significant move in the biomedical technology sector, reflecting the ongoing consolidation and strategic realignments among pharmaceutical companies.
3 months ago
11 Articles
Articles
Further Reading
You have 14 free stories remaining this month. Subscribe anytime for unlimited access.